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Abstract
Using ChIP Seq, we identiﬁed 556 and 467 putative STAT6 target sites in the Burkitt’s lymphoma cell
line Ramos and in the normal lung epithelial cell line BEAS2B, respectively. We also examined the pos-
itions and expression of transcriptional start sites (TSSs) in these cells using our TSS Seq method. We
observed that 44 and 132 genes in Ramos and BEAS2B, respectively, had STAT6 binding sites in proximal
regions of their previously reported TSSs that were up-regulated at the transcriptional level. In addition,
406 and 109 of the STAT6 target sites in Ramos and BEAS2B, respectively, were located in proximal
regions of previously uncharacterized TSSs. The target genes identiﬁed in Ramos and BEAS2B cells in
this study and in Th2 cells in previous studies rarely overlapped and differed in their identity.
Interestingly, ChIP Seq analyses of histone modiﬁcations and RNA polymerase II revealed that chromatin
formed an active structure in regions surrounding the STAT6 binding sites; this event also frequently
occurred in different cell types, although neither STAT6 binding nor TSS induction was observed. The
rough landscape of STAT6-responsive sites was found to be shaped by chromatin structure, but distinct
cellular responses were mainly mediated by distinct sets of transcription factors.
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1. Introduction
The signal transduction pathway initiated by IL-4
stimulation is involved in various biological phenom-
ena, such as Th2 cell differentiation, immunoglobulin
class switching in B cells and inﬂammatory responses
in epithelial cells.
1–3 Malfunctions of the IL-4 signal-
ling pathway cause improper responses in these cell
types that subsequently result in chronic allergic dis-
eases such as asthma and atopic disorders.
4,5 For
example, in asthma, IL-4 is excessively produced by
Th2 cells and induces differentiation and class switch-
ing of allergen-speciﬁc B cells towards IgE pro-
duction.
6,7 At the same time, IL-4 also initiates
response cascades in various cell types, such as eosi-
nophils, basophils, mast cells and epithelial cells.
8 In
particular, CCL11 (eotaxin-1) synthesis is enhanced
in epithelial cells,
9,10 and mucus-producing goblet
cells become hyperactive and differentiate.
11
Reﬂecting the pivotal roles of the IL-4 pathway in
allergic responses, knockout mice deﬁcient in signal-
ling molecules, such as the IL-4 receptor and STAT6,
show symptoms that resemble those of allergic dis-
orders.
12–14
In various cell types, the transcription factor (TF)
STAT6 is a common downstream effector of the IL-4
signalling pathway. When bound by IL-4, IL-4 receptor
a is phosphorylated by JAK kinases and recruits STAT6.
The JAK kinases phosphorylate STAT6, induce its
dimerization and facilitate its translocation to
nucleus, where it acts as a transcriptional activator.
15
Several dozen STAT6 target genes have been
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16 RETNLB,
17 SOCS1,
18,19
CD23A
20 and CCL11. It has also been shown that
the target sites of STAT6 have a consensus sequence:
TTCNNNNGAA. However, a comprehensive view of
the target genes of STAT6 remains elusive. In particu-
lar, previous studies mainly searched for STAT6 target
genes in T cells
21,22; target genes in other cell types
(such as B cells or epithelial cells) have not been
fully characterized.
Recently developed massively parallel sequencing
technologies coupled with chromatin immunopreci-
pitation (ChIP Seq) have enabled comprehensive ana-
lyses of binding sites for TFs.
23,24 Recent papers have
reported the comprehensive identiﬁcation of STAT6
target genes in Th2 cells in both mice and
humans.
22 ChIP Seq analysis has also been used to
comprehensively assess chromatin status by monitor-
ing changes in histone modiﬁcation patterns.
25–27
Indeed, for many genes in various cell types, epige-
netic changes have been shown to play important
roles in transcriptional regulation in response to cellu-
lar environmental changes. Moreover, we also devel-
oped a method to enable large-scale analysis of
transcriptional start sites (which we termed TSS Seq)
by combining our full-length cDNA technology
(oligo-capping) with massively parallel sequen-
cing.
28,29 In this method, a sequence adaptor necess-
ary for the sequencing reaction is introduced into the
mRNA as a cap-replacing oligo so that the region
immediately downstream of the TSS can be
sequenced (TSS tag).
30 We demonstrated that the
position of a TSS and its transcriptional level can be
analysed at the same time by digital counting of the
TSS tags. Integrative analysis of epigenomic and tran-
scriptomic data collectively revealed that the human
gene transcriptome and its regulation are truly
dynamic and depend on the cell type. Every cell
seems to have a unique chromatin status, harbouring
its own set of active promoters, and a large amount of
transcription occurs even from intergenic
regions.
31,32 These results again suggest that it is
essential to identify and characterize STAT6 target
genes and their regulation in a wider variety of cell
types to obtain a more complete view of the biological
relevance of the IL-4 signalling pathway.
In this paper, we characterized STAT6 target genes
and the chromatin status of the target sites by using
ChIP Seq to evaluate STAT6, RNA polymerase II (pol
II) and histone modiﬁcations. We further combined
the ChIP Seq data with TSS Seq data to monitor the
transcriptional consequences of STAT6 binding. We
identiﬁed and characterized 44 putative STAT6
target genes in the Ramos cell line, which is a
Burkitt’s lymphoma cell line, and 132 in the BEAS2B
cell line, which is a normal lung epithelial cell line.
We also compared the STAT6 target genes identiﬁed
in these cell types with recently reported STAT6
target genes in human Th2 cells. These results collec-
tively illustrate that different cell types have their own
mode of STAT6-mediated transcriptional regulation.
Here, we report that STAT6 has diverse target gene
repertoires depending on cell type.
2. Materials and methods
2.1. Sequence data
The short-read sequence archive data appearing in
this paper are registered in GenBank/DDBJ under
the following accession numbers: SRA008161,
SRA008162, SRA008163, SRA008164,
DRA000017, DRA000018, DRA000019,
DRA000020, DRA000021, DRA000022,
DRA000046, DRA000047, DRA000048,
DRA000049, DRA000050, DRA000051,
DRA000052, DRA000053, DRA000054,
DRA000055, DRA000056, DRA000057,
DRA000058, DRA000059, DRA000326,
DRA000327, DRA000328, DRA000329,
DRA000330, DRA000331, DRA000332,
DRA000333, DRA000334, DRA000335,
DRA000336, DRA000337, DRA000338,
DRA000339, DRA000340 and DRA000341.
2.2. Cell culture
CellsofthehumanBlymphomalineRamoswerecul-
tured in RPMI1640 medium (Nissui) supplemented
with 10% fetal bovine serum, 0.3 g/l L-glutamine
(GIBCO), 0.36% bicarbonate and 60 mg/l kanamycin
(GIBCO). Human lung epithelial BEAS2B cells were
maintained in Dulbecco’s modiﬁed Eagle’s medium:
Nutrient Mixture F-12 (GIBCO) with 10% fetal bovine
serum, 100 U/ml penicillin–100 mg/ml streptomycin
(GIBCO) and 1 mg/ml puromycin (BD Biosciences).
These cells were cultured at 378Ci na5 %C O 2 incuba-
tor. Ramos and BEAS2B cells were stimulated by
50 ng/ml recombinant rhIL-4 (BD Biosciences).
Ramos cells were stimulated 10 mg/ml human Anti-
IgM (BETHYL). RNA interference was accomplished by
transfecting cells with siGENOME SMARTpool STAT6
siRNA and siGENOME Non-Targeting siRNA #1
(Dharmacon). Short oligo-RNAs (50 nM) were trans-
fected using 2 ml/ml Dharmafect 1 transfection
reagent (Dharmacon) as recommended by the
manufacturer.
2.3. Construction of the ChIP Seq library
For each IP, 5   10
7 cells were stimulated with rhIL-
4a t3 7 8C for 30 min. Cells were ﬁxed with a 0.5%
formaldehyde solution (50 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES)-KOH, pH
7.5, 100 mM NaCl, 1 mM ethylendiaminetetraacetic
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(EGTA) and 5.5% formaldehyde) at room temperature
for 10 min. Glycine (150 mM) was added to quench
the cross-linking. Cells were rinsed twice with cold-
Phosphate Buffered Saline (PBS) and harvested. Each
cell pellet was resuspended in 5 ml of Lysis Buffer 1
(50 mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM
EDTA, 10% glycerol, 0.5% NP-40 and 0.25% Triton
X-100). The cell lysate was rocked at 48C for 10 min
and spun at 1500 rpm for 5 min at 48C. The super-
natant was discarded. Each cell pellet was resus-
pended in 5 ml of Lysis Buffer 2 (10 mM Tris–HCl,
pH 8.0, 200 mM NaCl, 1 mM EDTA and 0.5 mM
EGTA). The cell lysate was rocked at room temperature
for 10 min and spun at 1500 rpm for 5 min at 48C.
The supernatant was discarded. Each cell pellet was
resuspended in 1 ml of Lysis Buffer 3 (10 mM Tris–
HCl, pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, 0.1% Na-deoxycholate and 0.5% N-lauroylsar-
cosine). The cell lysate was sonicated with 10 cycles
of 30 s in ice water with a sonicator (TOMY SEIKO).
Triton X-100 (100 ml of a 10% solution) was added
to the sonicated cell lysate. The cell lysate was spun
at 14 000 rpm for 10 min. The supernatant was
transferred to a new tube, and 50 ml of the super-
natant was saved as whole cell extract (WCE)-DNA.
The WCE-DNA was stored at 2208C. The supernatant
was transferred to 100 ml of magnetic beads (Dynal)
that were bound to 10 mg of antibody. The samples
were rotated at 48C overnight and washed eight
times with 1 ml of Wash Buffer and once with TE
buffer containing 50 mM NaCl. Elution Buffer
(200 ml) was added and eluted at 658C for 15 min.
The samples were spun down, and the supernatant
was transferred to a new tube. The samples were incu-
bated at 658C overnight. WCE-DNA (50 ml) was
thawed, and 150 ml of Elution Buffer was added to
it. The samples were incubated at 658C overnight. TE
(200 ml) was added to the IP and WCE-DNA
samples. RNase (8 mlo f1 0 m g /ml; Funakosi) was
added. The samples were incubated at 378C for 2 h,
and 4 mlo f2 0 m g /ml proteinase K (Takara) was
added. The samples were incubated at 558C for 2 h.
Phenol chloroform extraction and ethanol precipi-
tation were performed. Samples destined for ChIP
Seq by Illumina GAIIx were prepared according to
the manufacturer’s instructions. Anti-STAT-6 antibody
(Santa Cruz, M-20), anti-RNA pol II antibody (Abcam,
ab817), anti-H3K4me3 antibody (ab1012) and anti-
H3Ac antibody (Millipore,
06–599) were used for the indicated experiments.
2.4. Construction of the TSS Seq library
Cells were seeded 48 h before stimulation. At 24 h
after seeding, the cells were transfected with STAT6
targeting and control siRNA and cultured for 24 h
for the indicated experiments. At 24 h after transfec-
tion, the transfected cells were stimulated with IL-4
and control 0.1% Bovine serum albumin (BSA) PBS
solution. At 24 h after stimulation, the cells were har-
vested, and RNA was extracted using an RNeasy Kit
(Qiagen). Fifty micrograms of the obtained total
RNA was subjected to oligo-capping with some modi-
ﬁcations of the original protocol; BAP-TAP-treated
total RNAs were ligated with 1.2 mg of RNA oligo
(50- AAUGAUACGGCGACCACCGAGAUCUACACUCUU
UCCCUACACGACGCUCUUCCGAUCUGG-30). After the
DNase I treatment (TaKaRa), polyA þ RNA was
selected using oligo-dT powder (Collaborative). First-
strand cDNA was synthesized from 10 pmol of
random hexamer primer (50-CAAGCAGAAGACGG
CATACGANNNNNNC-30) using Super Script II
(Invitrogen) at 128C for 1 h and 428C overnight.
Template RNA was degraded by alkaline treatment.
One-ﬁfth of the ﬁrst-strand cDNA was used as the
PCR template. For the PCR, a Gene Amp PCR kit
(PerkinElmer) was used with the PCR primers 50-
AATGATACGGCGACCACCGAG-30 and 50-CAAGCAGA
AGACGGCATACG-30 under the following reaction con-
ditions: 15 cycles of 948C for 1 min, 568C for 1 min
and 728C for 2 min. The PCR fragments were size-
fractionated by 12% polyacrylamide gel electrophor-
esis, and the fraction at 150–250 bp was recovered.
The quality and the quantity of the obtained single-
stranded ﬁrst-strand cDNA were assessed using a
BioAnalyzer (Agilent).
2.5. Deep sequencing and data processing of the ChIP
Seq and TSS Seq libraries
Approximately 1 ng of the size-fractionated cDNA
was used for sequencing using an Illumina GAIIx.
Statistics of the tags generated for each experiment
are summarized in Tables 1–3 and Supplementary
Fig. S1. The generated sequence tags were mapped
onto the human genomic sequence (hg18 as of
UCSC Genome Browser) using the sequence align-
ment Programme Eland (Illumina). Unmapped or
redundantly mapped sequences were removed from
the data set, and only uniquely mapped sequences
without any mismatches were used for further ana-
lyses. Positions relative to RefSeq genes were calcu-
lated based on the respective genomic coordinates.
Genomic coordinates of exons and the protein-
coding regions of the RefSeq transcripts are as
described in hg18.
For the ChIP Seq analysis, the binding sites of STAT6,
RNA pol II and histone modiﬁcations were identiﬁed
based on the short-read tag information as follows:
the region encompassed by each mapped tag
sequence was extended to 120 bp, which reﬂects
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genomic position, the number of overlapping
extended tags was counted. Based on the calculated
tag information, the sum of the included tags was
evaluated to determine whether more than a 10-
fold difference between the IP and the WCE was
present. Genomic regions in which positive enrich-
ment of the tags continued for more than 121 bp
were then selected. The statistical signiﬁcance for
this selection procedure compared with the back-
ground rate was evaluated using the Poisson probabil-
ities as previously described in the reference.
24
For the TSS Seq analysis, the TSS tags were clustered
into 500-bp bins. Representative TSSs were selected
as the position from which the largest number of
TSS tags was mapped. The selected representative
TSSs were used for further analyses. When the
genomic coordinates of a representative TSS was
located within 210 to þ1 kb of the 50-end of a
RefSeq transcript model, it was associated with the
RefSeq gene as the TSS of its authentic promoter. For
digital TSS-tag count analysis, TSS-tag counts were
normalized as parts per million tags and used for
further comparisons.
2.6. Other computational procedures
For Gene Ontology (GO) term analysis, GO terms
were associated with the identiﬁed STAT6 target
genes using loc2go at NCBI. GO term enrichment
was evaluated by calculating hypergeometric distri-
butions. The statistical signiﬁcance between the
expression levels and their fold inductions in Ramos
and BEAS2B cells was evaluated by the Wilcoxon
signed-rank test. To analyse the gene expression
changes of the TFs in Ramos and BEAS2B cells, 140
TFs were selected in TRANSFAC (Rel. 2010.1). Fold
changes of the expression levels in response to IL-4
stimulation were evaluated by digital TSS-tag counts.
The consensus sequences of the TFs were evaluated
using MATCH
33 with cut-off values determined using
minFP, which minimizes false-positive results. The
enrichment of the detected putative binding sites in
the active target and silent targets in Ramos and
BEAS2B cells was evaluated by calculating hypergeo-
metric distributions. Putative TF binding sites that
were signiﬁcantly enriched (P, 0.05) in the respect-
ive groups were selected.
2.7. Gene-speciﬁc PCR
For real-time PCR analysis of independent genes,
template DNA was prepared using essentially the
same protocol used for the short-read tag library con-
struction. PCR primers were designed using Primer3
(http://frodo.wi.mit.edu/primer3/). The PCR primers
used in this study are shown in Supplementary Table
S1. Semi-quantitative Reverse Transcription (RT)–
PCR was performed using an ABI 7900HT (ABI).
2.8. Electrophoresis Mobility Shift Assay (EMSA)
BEAS2B cells were stimulated with rhIL-4 at 378C
for 30 min. Cells were suspended in 400 ml of Buffer
A (10 mM HEPES-KOH, pH 7.8, 10 mM KCl, 0.1 mM
EDTA, 0.1% NP-40). Cells were spun at 5000 rpm for
1 min at 48C. The supernatant was discarded. Cell
pellet was resuspended in 100 ml of Buffer C
(50 mM HEPES-KOH, pH 7.8, 420 mM KCl, 0.1 mM
EDTA, 5 mM MgCl2, 20% Glycerol and 1 mM sodium
orthovanadate). The cell lysate was rotated at 48C
for 30 min and spun at 15000 rpm for 15 min at
48C. The supernatant was used as nuclear extract.
Table 2. Identiﬁcation of STAT6 targets: summary of TSS Seq
analysis
TSS Seq (IL-4 (þ)) TSS Seq (IL-4 (2))
# Ramos total reads 15 268 493 15 759 415
#BEAS2B total reads 14 818 816 11 628 747
#BEAS2B (siSTAT6) 14 122 877 13 789 254
Total reads 44 210 186 41 177 416
Table 3. Identiﬁcation of STAT6 targets: number of identiﬁed
STAT6 binding sites in the indicated populations
Ramos (pol II (þ);
TSS (þ))
BEAS2B (pol II (þ);
TSS (þ))
#total 556 (50) 467 (124)
Promoter 150 (30) 358 (121)
Alternative
promoter
205 (12) 33 (1)
Intergenic 201 (8) 76 (2)
The number of STAT6 binding sites at which pol II binding
and TSS induction were simultaneously observed (‘STAT6
targets’) is shown in parenthesis.
Table 1. Identiﬁcation of STAT6 targets: summary of the ChIP Seq
analyses of STAT6 and pol II
ChIP (STAT6) ChIP (Pol II)
Ramos
# total reads 19 099 520 21 903 761
# IL-4(þ) peaks 600 17 431
# IL-4(2) peaks 73 19 239
BEAS2B
# IP total reads 18 981 052 21 709 675
# IL-4(þ) peaks 773 13 457
# IL-4(2) peaks 314 8174
The numbers of peaks detected using the described par-
ameters are shown. The numbers of peaks detected using
different parameters are shown in Supplementary Fig. S1.
382 Characterization of STAT Target Genes [Vol. 18,Remaining procedures were performed using the
LightShift Chemiluminescent EMSA kit (Thermo
SCIENTIFIC). The DNA probe sequences used in this
study are shown in Supplementary Table S1.
3. Results and discussion
3.1. Identiﬁcation of putative STAT6 binding sites in
Ramos and BEAS2B cells
To identity STAT6 binding sites, we generated a total
of 19 099 520 and 18 981 052 36-bp sequence
ChIP Seq tags in Ramos and BEAS2B cells, respectively
(Tables 1–3). We selected genomic regions at which
ChIP Seq tags were enriched at the estimated false
detection rate of P , 5e26 (assuming a Poisson distri-
bution of background tags). We further selected the
sites at which no such enrichment was observed in
the absence of IL-4. In total, we identiﬁed 556 and
467 STAT6 binding sites that were speciﬁcally
detected in IL-4-stimulated Ramos and BEAS2B cells,
respectively (Fig. 1A and B). The validation analysis
using real-time RT–PCR for individual genes is pre-
sented in Supplementary Fig. S1A and B. Details of
the experimental and computational procedures are
also described in the ‘Material and methods’ and in
the Supplementary figures. See Supplementary Fig.
S1C and D for results using different parameters for
the computational target identiﬁcation procedure
and for the GenBank accession numbers of the
short-read tag data sets.
We analysed the genomic positions of the identiﬁed
STAT6 binding sites (Fig. 1C and D). In BEAS2B cells,
358 (77%) sites were located within 210 to þ1k b
of a RefSeq gene region (the 50-end of the most
upstream RefSeq transcript model was designated as
zero). In contrast, in Ramos cells, 150 (27%) of the
binding sites were located in these regions, whereas
37% were located in internal gene regions (Fig. 1C).
MEME analysis
34 of the binding sites in Ramos cells
detected the consensus sequence TTCNNNNGAA,
which matches previous studies.
35,36 However, a
different consensus sequence, TCTCGCG, was
detected in BEAS2B cells (Fig. 1E). For the results of
the validation analysis in the representative cases,
see Supplementary Fig. S2. These results may indicate
that STAT6 employs different modes of transcriptional
activation in these cells.
3.2. TSS SeqanalysisandChIP SeqanalysisofRNA polII
To directly analyse the transcriptional conse-
quences of STAT6 binding, particularly in Ramos and
BEAS2B cells, we constructed and analysed TSS Seq
libraries using the same materials. We expected that
TSS Seq analysis would allow us to associate the
binding sites in intergenic regions and genic regions
distant from the 50-end of the authentic RefSeq
transcript models with TSSs of previously uncharacter-
ized transcripts. We generated a total of 31 027 908
and 26 447 563 36 bp single-end read TSS tags in
Ramos and in BEAS2B cells, respectively. Of these,
22 227 238 (72%) and 20 964 221 (78%) of the
tags mapped within the 50-end exon of RefSeq genes
and upstream proximal regions in Ramos and
BEAS2B cells, respectively, indicating that the esti-
mated accuracy of the TSS tags for determining TSS
positions was 86% (also see Supplementary Fig.
S3C). The mapped tags were further clustered into
bins of 500 to represent putative promoter groups
(TSS clusters, TSCs). Consistent with our previous
results,
28 although the numbers of the TSCs were
generally large, those having TSS tags of .1 ppm (cor-
responding to one copy per cell, assuming every cell
has 1 million mRNA copies) represented a very
minor population (Supplementary Fig. S3D for stat-
istics). In total, there were 33 196 and 41 359 TSCs
with expression levels of .1 ppm in IL-4-stimulated
Ramos and BEAS2B cells, respectively. To further
ensure the validity of the TSS Seq analysis, we also
analysed pol II binding sites by ChIP Seq. We generated
and analysed 21 903 762 and 21 709 675 36-bp
single-end read tags and identiﬁed a total of 17 431
and 13 457 pol II binding sites with an estimated
false detection rate of P , 0.001 (Tables 1–3)i n
Ramos and BEAS2B cells, respectively (Supplemen
tary Fig. S1E–G). Of these, 63, 20 and 17% over-
lapped TSC regions located in the 50-ends, internal
parts and intergenic regions, respectively, of the
RefSeq genes.
We associated the STAT6 ChIP Seq data with the TSS
Seq data and the pol II ChIP Seq data. As summarized
in Tables 4 and 5, in BEAS2B cells, among 358 puta-
tive STAT6 binding sites that were identiﬁed within
RefSeq gene regions, 132 (37%) had TSCs that were
induced by at least 2-fold by IL4 stimulation and pol
II binding sites in their proximal region (210 to
1 kb compared with the binding site). In nine cases,
there were neither TSCs nor pol II binding signals in
the surrounding regions, but we found them in
other locations in the same RefSeq gene region. To
determine whether these TSCs are associated with
the STAT6 binding site, we conducted a TSS Seq analy-
sis using 27 912 131 TSS tags in STAT6-knockdown
BEAS2B cells (Table 2; also see Supplementary Fig.
S3E–G). In 85% of the STAT6 target TSSs, the tran-
scriptional induction indicated by digital TSS Seq-tag
counts was repressed in STAT6 knockdown cells, indi-
cating that the observed transcriptional induction at
the associated TSCs was directly mediated by STAT6
(Fig. 1F). Altogether, we identiﬁed 44 and 132
STAT6 target TSCs located at the 50-ends of RefSeq
genes, 45 and 9 TSCs previously uncharacterized
TSCs (putatively alternative promoters of the same
No. 5] A. Kanai et al. 383Figure 1. Identiﬁcation of STAT6 target RefSeq genes. (A) Examples of identiﬁed STAT6 targets in authentic RefSeq promoter regions in Ramos cells
(leftpanel)andBEAS2Bcells(rightpanel).STAT6bindingsitesareindicatedbyredlines.ExpressionchangesevaluatedbydigitalTSS-tagcountsare
also shown in the bottom margin.(B) STAT6 targets in putativealternative promoterregions (left panel) and in intergenic regions (right panel) in
Ramos cells. Upperand lower panels present the results from ChIP Seq and TSS Seq analyses, respectively. The IP used foreach ChIP Seq analysis is
showninthemargin.WCE,wholecellextractusedasabackgroundcontrol.(C)FrequencyofSTAT6bindingsitesrelativetoRefSeqregionsinRamos
cells (left panel) and BEAS2B cells (right panel). (D) Distance between STAT6 binding sites and 50-ends of RefSeq transcript models in Ramos cells
(red bar) and BEAS2B cells (blue bar). (E) Consensus sequences deduced f r o mS T A T 6b i n d i n gs i t e si nR a m o sc e l l s( u p p e rpa n e l)a n dB EAS 2 Bc e l l s
(lowerpanel).(F)FoldinductionoftheSTAT6targetTSSsevaluatedbydigitalTSS-tagcountsinSTAT6-knockdownBEAS2Bcells.They-axisindicates
the relative fold induction compared with that in wild-type BEAS2B cells. TSSs indicated byarrows showed reduced induction in knockdown cells.
384 Characterization of STAT Target Genes [Vol. 18,gene) and 34 and 6 TSCs located in intergenic regions
in Ramos and BEAS2B cells, respectively. Full lists of
the identiﬁed STAT6 targets in the respective cat-
egories are shown in Supplementary Table S2. For
the remainder of the 435 and 320 STAT6 binding
sites, there was no induced TSC associated with the
binding site (see the following sections for detailed
characterization). For the results of the similar ana-
lyses using antigen-stimulated Ramos cells, see
Supplementary Fig. S4A–E.
3.3. Characterization of STAT6 targets
We identiﬁed STAT6 targets in multiple categories
(see also Supplementary Fig. S5 for other examples).
3.3.1. protein-coding gene targets In Ramos and
BEAS2B cells, 44 and 132 RefSeq genes were identiﬁed
asSTAT6targetgenes,respectively,forwhichbindingof
STAT6 to the 50-end region wasobserved together with
the presence and induction of TSC and pol II binding
(Fig. 1A). Previously reported target genes such as the
SOCS1 in BEAS2B cells and low-afﬁnity Fc receptor
genes (CD23A) in Ramos cells are included, as are
some uncharacterized genes. For example, the MS4A1
gene (NM_021950) was identiﬁed as a STAT6 target
gene in Ramos cells. MS4A1 is a human B-lymphocyte
surface molecule, and in vitro studies with an MS4A1
monoclonal antibody showed that this gene plays
important roles in the regulation of B cell activation
and proliferation.
37,38 Moreover, this antibody is clini-
cally used as an anti-rheumatic drug.
39,40
Identiﬁcation of a STAT6-mediated pathway of MS4A1
induction may present a target for the design of novel
drugs. In general, GO term
41 enrichment analysis
showed that GO terms associated with protein
secretion and trafﬁcking molecules were enriched
among the STAT6 targets in Ramos cells. However, in
BEAS2B cells, GO terms associated with transcription
and chromatin remodelling were enriched (Fig. 2A).
STAT6 may have different repertoires of targets in
Ramos and BEAS2B cells.
3.3.2. Putative alternative promoter targets In
45 cases in Ramos cells and 9 cases in BEAS2B
cells, STAT6 binding sites were found to be associ-
ated with previously uncharacterized putative
alternative promoters of protein-coding genes (left
panel; Fig. 1B). For example, a putative STAT6-
responsive alternative promoter was identiﬁed in
Figure 1. Continued
Table 4. Epigenetic regulation of STAT6-mediated transcriptional
activation: summary of ChIP Seq analyses of histone
modiﬁcations
ChIP (H3K4me3) ChIP (H3Ac)
Ramos
# total reads 130 135 923 123 883 144
# IL-4(þ) peaks 27 364 46 294
# IL-4(2) peaks 26 128 49 953
BEAS2B
# IP total reads 117 611 512 124 648 546
# IL-4(þ) peaks 24 281 37 480
# IL-4(2) peaks 23 485 32 777
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(Supplementary Fig. S5). GAB1 is tyrosine-phos-
phorylated upon stimulation by various cytokines,
growth factors and antigen receptors.
Phosphorylated GAB1 interacts with phosphatidyl-
inositol 3-kinase (PI3K), and the N-terminal PH
domain of GAB1 binds to 3-phosphoinositide
(PI3).
42 Putative transcripts from the alternative
promoter of GAB1 lack the PH domain, which may
reduce PI3K lymphocyte activation via immunore-
ceptors and cytokine receptors by competing as a
PI3 docking-deﬁcient isoform.
3.3.3. Putative non-protein coding gene
targets Among the STAT6 binding sites
associated with intergenic TSCs, one TSC overlapped
a previously identiﬁed putative ncRNA gene (‘NR’
gene) according to the UCSC Genome Browser. In
one additional case, an intergenic TSC was associ-
ated with a fully sequenced full-length cDNA,
suggesting that STAT6 intergenic targets are mostly
uncharacterized transcripts.
43–45 The right panel in
Fig. 1B presents one such case. Although the mol-
ecular functions of these intergenic transcripts
remain elusive, this is the ﬁrst report to indicate
Table 5. Epigenetic regulation of STAT6-mediated transcriptional activation: the frequency of the STAT6 targets having the indicated
signals are shown for the indicated populations
Promoter Alternative promoter Intergenic
Ramos BEAS2B Ramos BEAS2B Ramos BEAS2B
#total 150 358 205 33 201 76
H3K4me3 (þ) 124 (83%) 327 (91%) 19 (9%) 3 (9%) 16 (8%) 7 (9%)
H3Ac (þ) 131 (87%) 321 (90%) 91 (44%) 2 (6%) 105 (52%) 10 (13%)
Pol II (þ) 116 (77%) 313 (87%) 47 (23%) 6 (18%) 51 (25%) 25 (33%)
TSC induction (þ) 44 (29%) 132 (37%) 45 (22%) 9 (27%) 32 (16%) 6 (8%)
Figure 2. Comparison of STAT6 target genes between Ramos and BEAS2B cells. (A) GO terms associated with the STAT6 target genes
identiﬁed in Ramos cells (top panel), BEAS2B cells (middle panel) and Th2 cells (bottom panel). (B) Overlap of the STAT6 target
genes in Ramos cells (red), BEAS2B cells (blue) and Th2 cells (green). (C) Expression levels (left panel) and fold induction (right
panels) in response to IL-4 stimulation evaluated by digital TSS-tag counts. Statistical signiﬁcance between the indicated populations
is shown in the margin. STAT6 target genes in Ramos and BEAS2B cells.
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expression of so-called putative non-coding RNA
transcripts.
3.4. Diverse regulation of STAT6 targets in different
cell types
We compared the STAT6 target genes identiﬁed in
Ramos cells with those in BEAS2B cells and found
that they did not overlap at all (Fig. 2B). Also, as
shown in Figs 1 and 2, STAT6 target genes showed dis-
tinct characteristics between Ramos and BEAS2B cells.
Speciﬁcally, the target genes had different consensus
binding sequences, different relative binding site pos-
itions compared with the RefSeq region and different
associated GO terms. We also included in the com-
parison STAT6 target sites in human Th2 cells that
were identiﬁed in a recent study.
22 The reported con-
sensus binding sequence of TTCNNNNGAA in Th2
cells was similar to the consensus sequence we ident-
iﬁed in Ramos cells. However, the reported target
genes in Th2 cells very rarely overlapped with those
in Ramos or BEAS2B cells. In contrast, the expression
and induction levels of the STAT6 target genes in
Ramos and BEAS2B cells were nearly equivalent
(Fig. 2C).
Having observed that different cells have different
repertoires of STAT6 targets even when they are simi-
larly activated, we speculated that this differential
regulation of STAT6 activation may be mediated by
distinct chromatin structures in distinct cell types.
We examined changes in histone modiﬁcation pat-
terns in response to IL-4 stimulation, namely tri-
methylation of lysine 4 (H3K4me3) and acetylation
(H3Ac) of histone 3, using ChIP Seq analysis of a
total of 496 279 125 36-bp single-end read tags
(Table 4). These histone modiﬁcations are thought
to be representative markers of active chromatin.
46
As shown in Fig. 3A, we observed that H3K4me3
and H3Ac were similarly enriched around the TSSs
of STAT6 target genes (STAT6-positive, pol II binding-
positive and TSS induction-positive genes) both in
Ramos and BEAS2B cells, suggesting that active tran-
scription occurs at the identiﬁed target sites.
Interestingly, in both cell types, active histone
markers were already present around the target sites
prior to IL-4 stimulation. It is possible that, upon IL-
4 stimulation, STAT6 is recruited to the chromatin
that is already programmed to be bound by STAT6
or other TFs (left panels; Fig. 3A and B; also see
Fig. 4B for a schematic representation).
We further examined the histone modiﬁcation pat-
terns in Ramos cells in regions that are STAT6 target
regions in BEAS2B cells but not in Ramos cells (we
denote these as ‘silent targets’ hereafter).
Interestingly, active histone markers were also
observed in Ramos cells even though these regions
were silent in this cell type; neither STAT6 binding
nor the presence of TSS tags was observed (right
panels; Fig. 3A). Pol II recruitment was even observed
in these regions (right bottom panel; Fig. 3A).
Although they are in a cellular context in which no
transcriptional induction occurs, these sites seem to
be resting in a prepared state until STAT6 is recruited.
3.5. Distinct modes of STAT6-mediated transcriptional
induction in different cell types
We also noticed that numerous STAT6 binding sites
in Ramos cells did not consequently induce transcrip-
tion even though STAT6 binding was clearly detected
by ChIP Seq and conﬁrmed by real-time PCR
(Tables 4 and 5; also see Supplementary Fig. S6 for
examples). We found that a majority of these STAT6
binding sites also resided within H3K4me3- and
H3Ac-positive regions and that pol II was frequently
recruited. Thus, only the induction of the TSS was
absent in these regions (Table 5). Similar observations
were also made regarding putative alternative promo-
ter binding sites of STAT6 and intergenic targets of
STAT6. In these cases, some additional factors
seemed to be missing, which hampered the full acti-
vation of transcription.
In BEAS2B cells, we also found a number of STAT6
binding sites lacking transcriptional induction, which
is similar to the case in Ramos cells (Table 5).
However, in BEAS2B cells, active histone markers
were found to be less prevalent around the silent
target regions (STAT6 target sites in Ramos cells),
and pol II was not bound in these regions (right
panels; Fig. 3B). In the active target sites, active
histone markers were already present prior to STAT6
binding, but pol II recruitment occurred only after
IL-4 stimulation (left panels; Fig. 3B). Results of a
similar analysis for Th2 target regions in Ramos and
BEAS2B cells are shown in Supplementary Fig. S7. It
is possible that STAT6-mediated transcriptional acti-
vation consists of multiple regulatory steps ranging
from the formation of active chromatin to the recruit-
ment of STAT6 and transcriptional activation, each of
which requires different factors that may be cell-
speciﬁc (Fig. 4B).
3.6. Transcriptional regulation of Ramos and BEAS2B
cells
To search for factors missing in Ramos and BEAS2B
cells that drive transcriptional activation in other cells,
we analysed the transcriptional induction of genes
encoding TFs in response to IL-4 stimulation by
counting TSS tags. For this purpose, we selected 183
previously functionally characterized TF genes from
TRANSFAC.
47 As shown in Fig. 4A, 45 (25%) of the
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or BEAS2B cells. Although similar numbers of TF genes
were up- or down-regulated, they rarely overlapped
between cell types (P ¼ 0.8). We further examined
which particular TFs had consensus binding sites
enriched in the population of STAT6 target genes,
although they were diluted in the surrounding
regions of the STAT6 binding sites at which no tran-
scriptional induction occurred. In BEAS2B cells, we
found that the predicted binding sites of FAC1,
which catalyses nucleosome sliding as a component
of the NURF complex,
48,49 were enriched (P , 3e-5)
in the former population. The expression of FAC1
was induced in response to IL-4 by 23-fold in
BEAS2B cells, whereas it was repressed by 50-fold in
Ramos cells. On the other hand, in Ramos cells, the
predicted binding sites of CEBP-g were found to be
enriched around the transcription-inducing STAT6
binding sites (P , 0.02), and transcription level of
CEBP-g was induced 27-fold upon IL-4 stimulation.
These TFs may be responsible for the cell-speciﬁc
regulation of STAT6 target genes. A complete list of
the identiﬁed TFs in the respective cell types and
their statistical signiﬁcance is shown in
Supplementary Fig. S8. These TFs should be the ﬁrst
targets in any attempt to elucidate the TFs that coop-
eratively regulate the transcription of STAT6 targets in
a cell-speciﬁc manner.
3.7. Conclusions
In this paper, we describe the characterization of
STAT6 target genes in Ramos and BEAS2B cells using
various types of massively parallel sequencing ana-
lyses. Among the 44 and 132 STAT6 target genes
identiﬁed in these two respective cell types, several
previously uncharacterized target genes were
included (Supplementary Table S2). The target
Figure 3. Status of histone modiﬁcations and pol II binding in the proximal regions of STAT6 target TSSs. (A) Distribution of the averaged
ChIP Seq tags for H3K4me3 (top panels), H3Ac (middle panels) and pol II (bottom panels) in Ramos cells. Data from active target genes
(STAT6 binding plus TSS induction in Ramos cells) are shown in the left panels, and data from silent target genes (STAT6 binding plus TSS
induction in BEAS2B cells but both negative in Ramos cells) are shown in the right panels. Blue, green, red and purple lines indicate the
results for the IP (IL-4 (þ)), IP (IL-4 (2)), WCE (IL-4 (þ)) and WCE (IL-4 (2)) experiments, respectively. On the x-axis, the position of the
associated TSS is designated as zero. (B) Results of an analysis similar to that shown in (A) in BEAS2B cells.
388 Characterization of STAT Target Genes [Vol. 18,genes identiﬁed in this study reside in various func-
tional categories in different cell types and expand
the opportunities to treat IL-4-related allergic diseases
by offering potential pharmacological targets.
It should also be noted that putative alternative
promoters were among the STAT6 targets identiﬁed
in this study. Because the potential transcripts from
these alternative promoters lack or have different N-
terminal protein-coding regions in many cases (exem-
pliﬁed in Fig. 1B), they are likely to have diversiﬁed
protein functions. Although elucidating the detailed
biological roles of these targets will require further
in-depth functional assays, it is likely that STAT6 also
utilizes these previously poorly characterized tran-
scripts in addition to canonical protein-coding tran-
scripts for the ﬁne tuning of target gene function.
We also identiﬁed STAT6 target genes in intergenic
regions of RefSeq transcripts that are likely to drive
non-protein coding transcripts. Multi-layered regu-
lation mediated by canonical promoters of protein-
coding genes, alternative promoters and non-coding
RNAs may further increase the complexity of the
responses to STAT6-mediated IL-4 stimulation in
various cell types, thereby collectively orchestrating
immune responses in humans. One of the greatest
advantages of integrating ChIP Seq data with TSS Seq
data may be that previously uncharacterized mol-
ecules could be analysed in a uniform platform.
We also found that different cell types have different
repertoires of STAT6 targets. In Ramos cells, genes
mainly involved in protein secretion and protein traf-
ﬁcking (such as MS4A1 and CCR6
50) were identiﬁed
as STAT6 targets, suggesting that one of the main bio-
logical roles of STAT6 activation is to change patterns
of secretory proteins and/or cell surface proteins
during the maturation of B cells. On the other hand,
in BEAS2B cells, genes involved in the alteration of
transcriptional programs (such as PTRH2
51 and
FUBP1
52) were found to be enriched. We further com-
pared the newly identiﬁed STAT6 targets in Ramos
and BEAS2B cells with recently identiﬁed STAT6
targets in Th2 cells. We found that neither overlapped
Figure 3. Continued
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targets bring distinct cellular consequences depend-
ing on cell types (Fig. 2).
We attempted to identify how different STAT6 tran-
scriptional activation programmes are realized in
different cell types. We found that the chromatin
status and pol II binding patterns were different
between Ramos and BEAS2B cells (Fig. 3). In BEAS2B
cells, the formation of active chromatin and recruit-
ment of pol II were speciﬁc to active STAT6 target
sites. Pol II recruitment occurred only upon IL-4
stimulation. In contrast, in Ramos cells, this event
sometimes occurred even around silent STAT6
targets, which are active in different cell types but
silent in this cell type. Different cell types seem to
have different modes of STAT6-mediated target acti-
vation. We therefore searched for factors that may
be necessary for full transcriptional activation of
STAT6 targets in Ramos and BEAS2B cells. As putative
cooperative factors for STAT6, we identiﬁed FAC1
(which is a component of the nucleosome sliding
complex NURF) in BEAS2B cells and CEBP-g (which is
a transcriptional activator
53) in Ramos cells. The
identiﬁcation of different categories of TFs in different
cell types may indicate that transcriptional induction
mediated by STAT6 requires modiﬁcation of the chro-
matin structure in BEAS2B cells, whereas the
recruitment of synergetic TFs is more important in
Ramos cells. Distinct cellular responses may be
mediated by the intrinsic chromatin status and
unique sets of TFs, and the factors that play the
most important roles may be different depending on
cell type.
We also found that STAT6 binding did not always
result in transcriptional activation. On the contrary,
the targets that were transcriptionally activated
upon STAT6 binding were relatively few in both
Ramos and BEAS2B cells. This feature of STAT6
binding was also observed in Th2 cells by other
groups.
22 There seems to be complex regulation of
transcriptional induction even after the formation of
active chromatin and the recruitment of TFs. The
advantage of using massively parallel sequencing as
a common platform is that genome-wide data can
be generated simultaneously for different steps of
transcriptional activation, ranging from the binding
of STAT6 and histone modiﬁcation to pol II binding
and transcriptional induction. It will be important to
determine which regulatory step is the most impor-
tant for each gene to fully understand STAT6-
mediated transcriptional activation mechanisms.
Further in-depth analyses of the identiﬁed target
genes will also be necessary to understand the mech-
anisms whereby these factors in their respective cell
Figure 4. Distinct regulation of STAT6 targets in different cell types. (A) Fold change of TF genes in response to IL-4 stimulation in Ramos
cells (red bar) and BEAS2B cells (blue bar) evaluated by digital TSS-tag counts. TFs were ordered by their fold induction in Ramos cells on
the x-axis. (B) Schematic representation of a model for distinct STAT6 activation in Ramos cells (upper panels) and BEAS2B cells (lower
panels). Inferred chromatin status and pol II binding are shown for the active targets in the left panel and for the silent targets in the
right panel. Green circles, STAT6; purple circles, pol II; yellow and orange circles, putative additional factors in Ramos and BEAS2B cells,
respectively; left and right columns, active and silent chromatin, respectively.
390 Characterization of STAT Target Genes [Vol. 18,types collectively induce necessary and/or harmful
immune responses in healthy and diseased individ-
uals. Biochemical and phenotypic analyses at the cel-
lular and organismal levels are still beyond the reach
of genome-wide approaches. However, the target
gene catalogue identiﬁed and characterized in this
study in different cell types should serve as a valuable
resource.
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